• <tr id="yyy80"></tr>
  • <sup id="yyy80"></sup>
  • <tfoot id="yyy80"><noscript id="yyy80"></noscript></tfoot>
  • 99热精品在线国产_美女午夜性视频免费_国产精品国产高清国产av_av欧美777_自拍偷自拍亚洲精品老妇_亚洲熟女精品中文字幕_www日本黄色视频网_国产精品野战在线观看 ?

    Solid organ transplantations and COVID-19 disease

    2021-12-21 08:29:28EmineAylinlmaznerzdemir
    World Journal of Transplantation 2021年12期

    Emine Aylin Y?lmaz, ?ner ?zdemir

    Emine Aylin Y?lmaz, ?ner ?zdemir, Division of Pediatric Allergy and Immunology, Sakarya University Medical Faculty, Adapazar? 54100, Sakarya, Turkey

    Abstract Tens of thousands of people worldwide became infected with syndrome coronavirus-2 (SARS-CoV-2). Death rate in general population is about 1%-6%, but this rate rises up to 15% in those with comorbidities. Recent publications showed that the clinical progression of this disease in organ recipients is more destructive, with a fatality rate of up to 14%-25%. We aimed to review the effect of pandemic on various transplantation patients. coronavirus disease 2019 (COVID-19) has not only interrupted waiting list patients’ lives; it has also impacted transplantation strategies, transplant surgeries and broke donation chains. COVID-19 was directly and indirectly accountable for 73% surplus in mortality of this population as compared to wait listed patients in earlier years. The impact of chronic immunosuppression on outcomes of COVID-19 remains unclear but understanding the immunological mechanisms related to the virus is critically important for the lifetime of transplantation and immune suppressed patients. It is hard to endorse changing anti-rejection therapy, as the existing data appraised is not adequate to advise substituting tacrolimus with cyclosporine during severe COVID-19 disease.

    Key Words: COVID-19; SARS-CoV-2; Solid organ transplantation

    INTRODUCTION

    Introduction and aim

    Tens of thousands of people worldwide became infected with syndrome coronavirus-2 (SARS-CoV-2)[1]. When the disease is clinically symptomatic; it presents with fever, cough, lymphopenia, dyspnea and, multiorgan failure in severe cases[2]. Death rate in general population is about 1%-6%, but this rate rises up to 15% in those with comorbidities[3]. Current publications showed that the clinical progression of this disease in organ recipients is more destructive, with a fatality rate of up to 14%-25%. We aimed to review the effect of pandemic on various transplantation patients[4].

    Negative effects of coronavirus disease 2019 in increasing waiting list of organ transplantations

    Coronavirus disease 2019 (COVID-19) has not only interrupted waiting list patients’ lives; it has also affected transplantation strategies, transplant surgeries and broke donation chains. COVID-19 was directly and indirectly accountable for 73% surplus in mortality of this population as compared to wait listed patients in former years[5].

    High COVID-19 afflicted areas observed more than 2.2 times bigger waiting list fatality as compared to prepandemic mortality in the United States[6]. In the United Kingdom, 10% of wait listed patients who developed COVID-19 died[7]. In France, as many as 42% of wait listed deaths in March and April 2020 were caused by COVID-19[5].

    Kidney transplant waiting list deaths increased by 43%, largest in any solid organ transplanted patient group on the waiting list[8,9]. In perspective, there was a 12% increase in deaths in patients on the lung transplant waiting list, an 8% increase in deaths on a liver transplant waiting list, and a 36% increase in deaths in patients on a heart transplant waiting list[10].

    Transplant and waiting list patients have similar death rates after admitted to the hospital for COVID-19 disease. A study has demonstrated a low absolute fatality risk from COVID-19 in transplanted and waitlisted cases, but a high and similar death rate when admitted to hospital, of around 30%. Death rate was higher in elderly transplant recipient cases[11].

    UNDESIRABLE EFFECTS OF IMMUNOSUPPRESSION ON COVID-19 IN TRANSPLANTATION PATIENTS

    The impact of chronic immunosuppression on outcomes of COVID-19 remains unclear but understanding the immunological mechanisms related to the virus is critically important for the lifetime of transplantation and immune suppressed patients.

    Given the reduced T-cell immunity, transplant recipients estimated to be at greater risk for serious bacterial and viral infections. The difficult problem is coronavirusinfected immunosuppressed and SOT patients who is taking whether intravenous immunoglobulin (IVIG), steroids, calcineurin inhibitors or mycophenolic acid. Solid organ transplantation itself covers various clinical conditions/issues resulting from kidney, liver, heart and lung transplantations (Table 1).

    Table 1 Therapeutic agents used during solid organ transplantation period and their side effects

    Angiotensin-converting enzyme-2 and dipeptidyl peptidase, expressed in proximal tubular cells, are identified as receptors for SARS-CoV and MERS-CoV[12]. The possible explanation for acute renal injury is the uptake of SARS-CoV-2 virus into the proximal tubular epithelium and virus infection inducing CD68+ -macrophage infiltration and enhancing complement C5b-C9 deposition on tubules[13].

    Acute renal injury is one of the commonest complications of COVID-19. It was seen in 30%-89% of patients with kidney transplantation. Acute renal injury has developed as a result of many factors like decreased renal perfusion and cytokine storm[14]. To date, minimizing the utilization of antivirals and immunosuppressive therapy has been recommended, but the evidence has been weak to support these recommendations[1]. Hypothetical, conversion to cyclosporine, in kidney transplant patients with COVID-19 has both antiviral potency and immunomodulatory effects; it may also help to avoid graft rejection during the infection[1].

    Several studies have reported that immunosuppression may be a possible risk factor for coronavirus-related pneumonia in a patient[13]. For kidney transplant recipients diagnosed with SARS-CoV-2, it may be reasonable to use cyclosporine because of its antiviral and immune modulatory effects[13]. According to various clinical studies, severe pneumonia has been more widely reported in patients receiving anti-rejection and induction therapies, possibly due to immunosuppression[15].

    The management of heart transplant recipients becomes more complex as these heart transplant patients require more intense immunosuppression than other SOT recipients[16]. In addition to the present complexity, COVID-19 have a potential effect on both primary and secondary myocardial injuries[17]. These cases are constantly utilizing long-term immunosuppressive therapy and at a high risk to develop unwanted effects. Although they have adequate heart function, this population must be thought as very brittle owing to the existence of several comorbidities like chronic renal disease associated with a long exposure to immunosuppressants. In a transplanted cases’ cohort, time-dependent comorbidities along with older age, such as calcineurin inhibitor nephrotoxicity and other common complications of immunosuppressive management, could also be harmful[18].

    Transplant recipients are thought by some authors as a high-risk group for COVID-19 since they take lifetime immunosuppressive treatment. Immunomodulatory agents could improve immune reaction, but this could yield to an escalation in viral load and postponed disease salvage. Remarkably, calcineurin inhibitors, the most commonly used immunosuppressive agent in lung transplant recipients, have shown impressive capacities to inhibit the replication of coronaviruses. Therefore, it was suggested that basic immunomodulation could defend lung transplant patients against the most severe clinical pictures of COVID-19 disease[19].

    Calcineurin inhibitors, antimetabolites, and glucocorticosteroids are the most commonly used as standard immunosuppressants; nonetheless, in COVID-19 confirmed patients, antimetabolites were generally stopped while prescription of glucocorticosteroids was continued in management or even amplified in dosage. It was thought as essential to use suitable doses of glucocorticosteroids through the process, as it could subdue hyperinflammatory reaction and stimulate the recovery from pneumonia without severe unwanted effects[20].

    Impact of co-infections (fungal) with COVID-19 in transplantation patients

    Impact of co-infections (bacterial or viral) with COVID-19 disease in SOT patients could be severe and mortal. To the best of our knowledge, specific co-infections (bacterial or viral) related with SARS-CoV-2 in SOT patients have not been reported much. However, SARS-CoV-2 might rise the risk of invasive pulmonary aspergillosis (?PA) development in these patients. Although several case reports and small series have been described in the literature, infrequent information is obtainable concerning COVID-19-related ?PA in SOT cases. A case of a renal SOT recipient with severe COVID-19 was later diagnosed with IPA. After beginning of isavuconazole with nebulized liposomal amphotericin B combination treatment and the withdrawal of immunosuppression, ?PA was improved[21].

    Other risk factors for COVID-19 development and mortality in transplantation patients

    SOT cases with COVID-19 had a tendency to greater mortality compared with non-SOT controls, although it was not always found to be statistically significant[20,22]. Immunosuppression and comorbidities might put SOT patients at upper risk from COVID-19, as proposed by new case series[23]. In the overall literature, some factors were shown to be independently related with COVID-19 included non-white race and comorbidities, comprising obesity, diabetes, asthma and chronic obstructive pulmonary disease[24]. Nevertheless, no factors were demonstrated to be related with fatality, other than being elderly in those who had been transplanted in the literature[11].

    A few studies have clearly compared consequences between SOT and non-SOT patients with COVID-19 disease. A retrospective matched cohort single-center study evaluated effects of COVID-19 and the effect of immunomodulation on cytokine release syndrome of COVID-19 in SOT patients. Overall, SOT recipient cases had equal fatality to non-SOT cases, although more SOT cases received tocilizumab (63%vs48%) and steroids (37%vs20%)[25]. In another study, 45 SOTvs2427 non-SOT cases hospitalized with COVID-19 to a health-care system were compared. There were no statistically meaningful differences between SOT and non-SOT in maximum illness severity score, length-of- stay, or mortality. Regardless of a greater risk profile, SOT recipients had a significantly faster drop in disease severity over time compared with non-SOT cases[23]. Chaudhryet al[26] compared consequences of 35 SOT cases with 100 non-SOT cases that were admitted with COVID-19 at a single center, and detected that a combined consequence [intensive care units (ICU) admission, intubation, hospital fatality] was similar between these 2 groups, even though comorbidities and acute renal damage were more usual in the SOT case group[26]. Generally, SOT cases were more likely to take COVID-19 specific treatments and to need ICU admission. However, fatality (23.08% in SOTvs23.14% in non-SOT) and highest level of supplementary oxygen needed during admission did not significantly vary between these groups[27].

    As a result from overall literature, mortality in SOT recipients compared to controls (non-SOT patients) has been detected as similar and the SOT programs should not be stopped and are better to be continued.

    VARIOUS THERAPEUTIC OPTIONS OF COVID-19 DISEASE IN TRANSPLANTED PATIENTS

    Convalescent immune plasma (CIP) infusion has been utilized in the therapy of other infectious diseases for more than a century[28], under the notion that passive immunization can push the immune system to prevent the disease progression until a specific immune response is developed in the afflicted person[29]. However, the use of CIP did not improve survival in non-transplant patients with severe COVID-19 disease[29]. According to a randomized control trials study at day 30, no significant difference was reported between the CIP and the placebo groups[29].

    A course of IVIG at dose of 1 g/kg was given as an immunomodulatory therapy in patients with serum immunoglobulin G (IgG) level < 700 mg/dL. Antiviral treatment was not administered in any group. According to a large, randomized open-label trial, dexamethasone was related with lower fatality in patients necessitating mechanical ventilation or supplemental oxygen, compared with a standard care[30].

    Mycophenolate has a cytostatic effect on activated lymphocytes. In COVID-19, the virus SARS-CoV-2 has a direct cytotoxic effect on CD8+ -lymphocytes, thus explaining the relation between lymphopenia and poorer outcomes. Consequently, mycophen- olate and SARS-CoV-2 may reveal a synergic and side effect on diminishing peripheral lymphocytes, which would be accountable for a deviant immune modification as shown with other viruses. On the contrary, mechanistic target of rapamycin (mTOR) inhibitors enhance the quality and functionality of memory T-cells and lessen the replication of numerous viruses[31].

    Cyclosporine can be beneficial at any moment through the progress of the disease given its impact on the inhibition of viral replication, maintenance of renal graft and down regulation of the immune reaction. Cyclosporine and tacrolimus are the most utilized calcineurin inhibitors in regular clinical practice for inhibition of alloimmune response in transplantation. Calcineurin inhibitors subdue the immune system and the primary action is inhibition of interleukin-2 (IL-2) production in T-cells. Cyclosporine and tacrolimus are chemically different molecules. Calcineurin inhibitors attach to intracellular cyclophilin, which is an immunophilin, and this calcineurin inhibitorimmunophilin complex inhibits nuclear factor of activated T-cells (NFAT). As a result of NFAT inhibition, cytokine transcription and T-cell activation are blocked[32]. The cyclosporine level needed to prevent virus replication surpasses by far the serum levels that characteristically are well below 200 ng/mL[32]. This indicates that the dose utilized to manage most patients with cyclosporine is too low to successfully eliminate the virus. One of the issues is to reach adequate tissue level, as the key virus load is in the respiratory tract and lungs rather than in serum and the cyclosporine concentration in the lungs is lesser than in serum[32]. Additionally, the necessary dosage for vigorously treating severe COVID-19 patients would be 3-6 times greater, which in turn would trigger severe adverse and possible toxic effects, specifically nephrotoxicity[32]. Inhaled cyclosporine has been tried in animals, healthy volunteers and pulmonary transplantation recipients and the pulmonary amount of inhaled cyclosporine is three times more than when systemically administered[32].

    Calcineurin inhibitors, such as cyclosporine A and tacrolimus, have a significant role in continuing immunosuppression after SOT. Those medications have a slight therapeutic window, and individual doses and drug management watching are required. A significant amount of cases suffer from short- or long-term calcineurin inhibitors toxicity, with renal dysfunction, hypertension, neurotoxicity and metabolic instabilities[33]. Dose minimization is related with a modest improvement in kidney function, but persistent injury is detected on biopsies if the calcineurin inhibitors are sustained. Calcineurin inhibitor cessation may be the best option by providing calcineurin inhibitors through the early period of immunologic graft damage and then changing them to less nephrotoxic drugs before imperative renal damage happens[34].

    Prophylactic lessening of immunosuppression due to fear of COVID-19 disease is not recommended in SOT recipients. With maintenance immunosuppressive management, glucocorticosteroids can be sustained during COVID-19 disease[35]. Sustaining other immunosuppressive medications with lowest effective dose/blood concentration is recommended for cases having mild to moderate COVID-19. Withdrawal of antimetabolitese.g.mycophenolate mofetil and maybe inhibitors of mTOR such as sirolimus is recommended in moderate to severe COVID-19. Calcineurin inhibitors may be sustained or replaced for mTOR inhibitors with lowermost therapeutic levels in moderate to severe COVID-19. If sustained in COVID-19 cases, therapeutic drug watching of calcineurin/mTOR inhibitors and proper dose lessening is suggested in combination with protease inhibitors, hydroxychloroquine/chloroquine, or IL-1/IL-6 receptor antagonists. Checking hemogram is suggested in cases using antimetabolite drugs or mTOR inhibitors. Drug dose adjustment/evasion should be thought for chloroquine, atazanavir, oseltamivir, ribavirin, anakinra, and Janus associated kinase (Jak) inhibitors in cases with organ dysfunctions[36].

    Anti-COVID-19 medicationse.g.lopinavir/ritonavir and hydroxychloroquine have not been tried by laborious clinical trials. These medications may be utilized cautiously for common patients with COVID-19, but for SOT recipients using long-term immunosuppressive management, antiviral medications should be meticulously chosen. Moreover, the senior SOT patients frequently afflicted with hepatic and renal dysfunction of varying degrees, resulting in worse drug metabolism. The combination of lopinavir/ritonavir and hydroxychloroquine is blamable for extreme tacrolimus trough level with unwanted effects[37].

    COVID-19 VACCINATION IN TRANSPLANTATION PATIENTS

    In transplant recipient patients, the COVID-19 vaccine is a way to protect these patients when there is no definitive cure for COVID-19. On waiting list of cases with COVID-19, serologic studies have showed that IgM levels increase 5–10 d after infection onset. IgG development classically follows an IgM response development within 12–14 d of symptom onset in most patients[9]. Follow-up studies suggest that these responses last for at least 5 months succeeding infection and can confer immunity against repeated SARS-CoV-2 infections[9].

    Growing evidence indicates that SOT recipients who take mRNA-based vaccines have low immunization rates[38]. Less than half of the vaccinated transplant cases demonstrated antibodies against the SARS-CoV-2 spike protein[38]. Although immunosuppressant agents are thought to have a key role during this course, the appearance of severe COVID-19 disease after mRNA-based vaccination in immunocompetent or immunocompromised individuals has not yet been described[38]. A possible reason for this might owe to lack of humoral response, together with a restricted or deficient T-cell response, even after the second dose of the vaccination[38]. Live (replication-competent) vaccines are usually contraindicated in immunocompromised subjects due to a risk of vaccine-acquired disease[39]. These vaccines contain intact virions that are engineered to incorporate the gene encoding the SARS-CoV-2 spike protein, somehow influences the viral vector’s capacity to competently infect cells and increases spike gene delivery[39]. It should be emphasized that immunosuppression isn’t considered as a contraindication to their use, despite the theoretical concerns with replication-deficient viral vector-based vaccines. SARS-CoV-2 vaccines have significant potential to decrease COVID-19-associated morbidity and mortality among recipients of SOT, including kidney transplants[39].

    In a study, 14 SOT recipients were diagnosed with COVID-19 after 24 d from application of vaccines. One patient deceased, 2 patients were hospitalized and 11 patients were improved at home. 50% of infected cases were hospitalized for the management. There was enough data to issue warnings that immunologically incompetent people should remain to practice firm COVID-19 precautions after vaccination and direction given to the overall people may not be relevant to the SOT patients[40].

    SOME ISSUES OF TRANSPLANTATION PATIENTS DURING COVID-19 PANDEMIC

    As access to hospitals becomes easier; the determination of SARS-CoV-2 infected patients with mild symptoms which would otherwise to be missed in the overall population is increasing.

    Fatality rates were lesser than those detected in the age- and gender-matched common population, thereby signifying that chronic immunosuppression could result in a certain protective effect against the most severe types of COVID-19. According to a multi-center study in Istanbul, the usage of cyclosporine was related with lesser incidence of fatality. On the contrary, rejection treatment was recognized as a risk factor for mortality[15]. Nevertheless, in cases taking mycophenolate, dose lessening, or temporary change to calcineurin inhibitors or everolimus may be thought until complete rescue from COVID-19[31].

    It is hard to endorse changing anti-rejection therapy, as the existing data appraised is not adequate to endorse substituting tacrolimus with cyclosporine during severe COVID-19 disease[32]. Nonetheless, revised guidelines should advise to continue cyclosporine use to the cases during COVID-19 except in some of patients having like kidney failure, severe leucopenia or increased serum cyclosporine levels. A change from tacrolimus to cyclosporine would be founded only on affirmative observational documents with a supposed advantage for COVID-19 illness, but with a likely greater risk of refusal and controlled studies are necessary to exam whether this change is suitable or not[32]. We need to identify which solid organ transplant recipients profit from specific therapies, the ideal timing of these therapies and the balance of benefits and risks of these therapies, such as late secondary infections. We have to embolden clinical trials and observational researches in the future to incorporate solid organ transplant recipients. Long-term follow up of solid organ transplant recipients will be important in order to clarify for these guidelines. For the safety of recipients, testing donors for SARS-CoV-2 has become a cornerstone of kidney transplant practice[9].

    CONCLUSION

    Although negative effects of COVID-19 on increasing waiting list and undesirable effects of immunosuppression on COVID-19 disease in SOT patients; the literature data support continuation of transplant programs during the COVID-19 era[11].

    嫁个100分男人电影在线观看| 国产精品秋霞免费鲁丝片| 欧美日韩中文字幕国产精品一区二区三区 | 黑人巨大精品欧美一区二区蜜桃| 国产视频一区二区在线看| 又黄又爽又免费观看的视频| 成人永久免费在线观看视频| 精品高清国产在线一区| 久久久国产一区二区| 国产成人欧美在线观看| 97超级碰碰碰精品色视频在线观看| 久9热在线精品视频| 大型av网站在线播放| 少妇裸体淫交视频免费看高清 | 黄色丝袜av网址大全| 性欧美人与动物交配| 国产亚洲欧美98| 两人在一起打扑克的视频| 亚洲欧美激情综合另类| 99香蕉大伊视频| 亚洲七黄色美女视频| 日韩三级视频一区二区三区| 精品久久久久久,| 丰满饥渴人妻一区二区三| 日韩国内少妇激情av| 精品久久久精品久久久| 亚洲色图综合在线观看| 亚洲在线自拍视频| 免费av中文字幕在线| 三级毛片av免费| 日韩av在线大香蕉| 亚洲av熟女| 国产成人精品久久二区二区91| 中文字幕另类日韩欧美亚洲嫩草| 久久久久久久午夜电影 | 十八禁人妻一区二区| 亚洲一区二区三区欧美精品| 国产av精品麻豆| 久久久久久久午夜电影 | 美女 人体艺术 gogo| 69精品国产乱码久久久| 久久九九热精品免费| 两性夫妻黄色片| 亚洲人成电影观看| 午夜亚洲福利在线播放| 国内毛片毛片毛片毛片毛片| 美女高潮到喷水免费观看| 精品乱码久久久久久99久播| 免费av毛片视频| 在线观看免费视频网站a站| 亚洲国产精品sss在线观看 | 男女下面进入的视频免费午夜 | 久久久久国产精品人妻aⅴ院| 亚洲专区字幕在线| 岛国在线观看网站| 午夜激情av网站| 手机成人av网站| 国产免费男女视频| 久久精品国产综合久久久| 国产99久久九九免费精品| 淫妇啪啪啪对白视频| 亚洲精品国产色婷婷电影| 久久热在线av| 制服人妻中文乱码| 精品久久久久久电影网| 国产av又大| 免费搜索国产男女视频| 国产精品自产拍在线观看55亚洲| 91av网站免费观看| 色婷婷av一区二区三区视频| 国产精品电影一区二区三区| 身体一侧抽搐| avwww免费| 在线天堂中文资源库| 午夜福利,免费看| 国产xxxxx性猛交| 久久国产乱子伦精品免费另类| 99国产极品粉嫩在线观看| 国产成人欧美| 在线观看www视频免费| 亚洲中文字幕日韩| 超碰97精品在线观看| 超碰97精品在线观看| 成年人黄色毛片网站| 国产免费现黄频在线看| 亚洲国产欧美一区二区综合| 久久久久国产一级毛片高清牌| 丝袜美足系列| 亚洲伊人色综图| 男女下面进入的视频免费午夜 | 国产熟女午夜一区二区三区| 精品久久久久久久久久免费视频 | 亚洲伊人色综图| 午夜a级毛片| 亚洲性夜色夜夜综合| 成年人黄色毛片网站| 首页视频小说图片口味搜索| 亚洲午夜理论影院| 国产视频一区二区在线看| 久久国产精品男人的天堂亚洲| 国产一区二区三区在线臀色熟女 | 国产亚洲精品一区二区www| 免费在线观看影片大全网站| 国产一区二区在线av高清观看| 在线观看日韩欧美| 成人三级做爰电影| 曰老女人黄片| 国产精品一区二区三区四区久久 | 精品久久蜜臀av无| 久久精品亚洲精品国产色婷小说| 亚洲成人精品中文字幕电影 | 如日韩欧美国产精品一区二区三区| 午夜成年电影在线免费观看| 色婷婷久久久亚洲欧美| 国产精品香港三级国产av潘金莲| 人成视频在线观看免费观看| 国产精品 欧美亚洲| 免费在线观看视频国产中文字幕亚洲| 亚洲 国产 在线| 中文字幕人妻丝袜一区二区| 国产av又大| 色尼玛亚洲综合影院| 热99国产精品久久久久久7| 欧美一区二区精品小视频在线| 999久久久国产精品视频| 老汉色∧v一级毛片| 亚洲成人久久性| 欧美日本亚洲视频在线播放| avwww免费| 天天添夜夜摸| 中亚洲国语对白在线视频| 91大片在线观看| 亚洲精品中文字幕在线视频| 精品国产乱码久久久久久男人| 久久久国产一区二区| 夜夜看夜夜爽夜夜摸 | 精品久久久久久成人av| 老司机亚洲免费影院| 亚洲精品在线观看二区| 成年人免费黄色播放视频| 久久九九热精品免费| 黄色丝袜av网址大全| 成年版毛片免费区| 国产精品香港三级国产av潘金莲| 国产亚洲欧美在线一区二区| 90打野战视频偷拍视频| 成人亚洲精品一区在线观看| 黄色视频,在线免费观看| 国产精品av久久久久免费| 日本a在线网址| 免费观看人在逋| 日韩高清综合在线| 日本wwww免费看| 日本vs欧美在线观看视频| 91麻豆av在线| 人人澡人人妻人| 欧美最黄视频在线播放免费 | 一本综合久久免费| 久久香蕉精品热| 18禁观看日本| 久久国产精品男人的天堂亚洲| 精品国产美女av久久久久小说| 午夜福利一区二区在线看| 国产欧美日韩精品亚洲av| 久久久久久大精品| 一个人观看的视频www高清免费观看 | 天堂影院成人在线观看| 多毛熟女@视频| 黄色a级毛片大全视频| 搡老熟女国产l中国老女人| 欧美精品亚洲一区二区| 妹子高潮喷水视频| 一进一出抽搐gif免费好疼 | 啦啦啦 在线观看视频| 国产精品自产拍在线观看55亚洲| 国产精品自产拍在线观看55亚洲| 一级片免费观看大全| 国产麻豆69| 丰满人妻熟妇乱又伦精品不卡| 麻豆一二三区av精品| 又紧又爽又黄一区二区| 每晚都被弄得嗷嗷叫到高潮| 国产精品香港三级国产av潘金莲| 午夜福利免费观看在线| 18美女黄网站色大片免费观看| 两个人免费观看高清视频| 亚洲国产精品sss在线观看 | 亚洲av美国av| 99在线人妻在线中文字幕| 天堂中文最新版在线下载| 高清毛片免费观看视频网站 | 人人妻人人澡人人看| 热99re8久久精品国产| 午夜久久久在线观看| 99久久99久久久精品蜜桃| 一二三四在线观看免费中文在| 老司机靠b影院| 在线观看免费视频网站a站| 亚洲中文av在线| av网站免费在线观看视频| 视频区图区小说| 正在播放国产对白刺激| 日韩免费高清中文字幕av| 久久精品亚洲熟妇少妇任你| 欧美一区二区精品小视频在线| 久热这里只有精品99| 亚洲精品国产精品久久久不卡| 交换朋友夫妻互换小说| 成人黄色视频免费在线看| 成人国语在线视频| xxxhd国产人妻xxx| 色老头精品视频在线观看| 国产99白浆流出| 波多野结衣av一区二区av| 一二三四社区在线视频社区8| 亚洲九九香蕉| 久久久精品国产亚洲av高清涩受| 真人做人爱边吃奶动态| 亚洲欧美日韩另类电影网站| 亚洲国产看品久久| 欧美成人性av电影在线观看| 久久精品国产99精品国产亚洲性色 | 久久中文字幕人妻熟女| 亚洲人成伊人成综合网2020| 一级毛片精品| 精品电影一区二区在线| 亚洲av日韩精品久久久久久密| 欧美日韩一级在线毛片| 国产精品电影一区二区三区| ponron亚洲| 国产午夜精品久久久久久| 99精品久久久久人妻精品| 亚洲 欧美一区二区三区| 国产精品综合久久久久久久免费 | 日本 av在线| 电影成人av| 国产精品久久电影中文字幕| 国产乱人伦免费视频| 日韩欧美一区视频在线观看| 老鸭窝网址在线观看| 欧洲精品卡2卡3卡4卡5卡区| 精品福利观看| 国产精品久久久人人做人人爽| 老鸭窝网址在线观看| 夫妻午夜视频| 午夜两性在线视频| 一二三四社区在线视频社区8| 国产欧美日韩一区二区精品| 丁香六月欧美| 波多野结衣高清无吗| 一个人免费在线观看的高清视频| 美女 人体艺术 gogo| 亚洲午夜理论影院| 日韩成人在线观看一区二区三区| 国内毛片毛片毛片毛片毛片| 大码成人一级视频| 色老头精品视频在线观看| 男女做爰动态图高潮gif福利片 | 国产成人精品在线电影| 免费不卡黄色视频| 久久精品亚洲精品国产色婷小说| 精品久久久久久,| 大型av网站在线播放| www.熟女人妻精品国产| 一二三四在线观看免费中文在| 国产一卡二卡三卡精品| 香蕉国产在线看| 91精品国产国语对白视频| 欧美+亚洲+日韩+国产| 亚洲性夜色夜夜综合| 大码成人一级视频| 国产精品免费视频内射| 88av欧美| 热99re8久久精品国产| 亚洲欧美一区二区三区久久| 国产三级在线视频| 亚洲七黄色美女视频| 色综合欧美亚洲国产小说| 免费在线观看视频国产中文字幕亚洲| 在线观看一区二区三区激情| 夜夜爽天天搞| 91老司机精品| 天天躁夜夜躁狠狠躁躁| 久久人妻福利社区极品人妻图片| 国产国语露脸激情在线看| 可以在线观看毛片的网站| 午夜免费成人在线视频| 天天添夜夜摸| 熟女少妇亚洲综合色aaa.| 欧美精品亚洲一区二区| 欧美黑人欧美精品刺激| 无人区码免费观看不卡| 超碰成人久久| 一a级毛片在线观看| 久久精品成人免费网站| 欧美最黄视频在线播放免费 | 欧美成人性av电影在线观看| 男女高潮啪啪啪动态图| 国产一区二区三区视频了| 精品久久久久久久毛片微露脸| 欧美一级毛片孕妇| 麻豆成人av在线观看| 亚洲成av片中文字幕在线观看| 人人妻人人澡人人看| 中文字幕精品免费在线观看视频| 日韩精品免费视频一区二区三区| 大香蕉久久成人网| 国产成人精品久久二区二区免费| 黄色视频,在线免费观看| 成人三级做爰电影| 超碰97精品在线观看| 叶爱在线成人免费视频播放| 桃色一区二区三区在线观看| a级毛片黄视频| 99热只有精品国产| 精品国产一区二区久久| 欧美日韩瑟瑟在线播放| 欧美激情 高清一区二区三区| 18禁黄网站禁片午夜丰满| 国产精品乱码一区二三区的特点 | 老汉色av国产亚洲站长工具| 桃色一区二区三区在线观看| 老熟妇乱子伦视频在线观看| 亚洲熟妇中文字幕五十中出 | 好男人电影高清在线观看| 午夜亚洲福利在线播放| 精品日产1卡2卡| 亚洲精品在线美女| 99精国产麻豆久久婷婷| svipshipincom国产片| 欧美日韩亚洲高清精品| 日本a在线网址| 人人澡人人妻人| 91成人精品电影| 麻豆av在线久日| 99国产精品99久久久久| 精品一品国产午夜福利视频| 麻豆国产av国片精品| 一本大道久久a久久精品| 久久精品国产清高在天天线| 美女 人体艺术 gogo| 777久久人妻少妇嫩草av网站| 国产一区二区在线av高清观看| e午夜精品久久久久久久| 一二三四在线观看免费中文在| 国产一区二区激情短视频| 可以免费在线观看a视频的电影网站| 国产视频一区二区在线看| 亚洲av电影在线进入| 国产精品久久电影中文字幕| 老熟妇仑乱视频hdxx| 在线看a的网站| 久久影院123| 女同久久另类99精品国产91| 国产三级黄色录像| 亚洲avbb在线观看| 国产欧美日韩一区二区三区在线| 亚洲av熟女| 我的亚洲天堂| 欧美av亚洲av综合av国产av| 久久性视频一级片| 日韩国内少妇激情av| 欧美激情 高清一区二区三区| 97超级碰碰碰精品色视频在线观看| 变态另类成人亚洲欧美熟女 | 亚洲国产精品一区二区三区在线| 50天的宝宝边吃奶边哭怎么回事| 久久久国产欧美日韩av| 十八禁人妻一区二区| 成人永久免费在线观看视频| 免费在线观看完整版高清| 夜夜夜夜夜久久久久| 黄网站色视频无遮挡免费观看| 俄罗斯特黄特色一大片| 最新美女视频免费是黄的| 久久人人精品亚洲av| 中文欧美无线码| 国产精品久久久久成人av| 88av欧美| 熟女少妇亚洲综合色aaa.| 好男人电影高清在线观看| 麻豆av在线久日| 香蕉久久夜色| 国产精品二区激情视频| 成熟少妇高潮喷水视频| 大型黄色视频在线免费观看| av网站免费在线观看视频| 久久久久久久久中文| 18禁国产床啪视频网站| 女人精品久久久久毛片| 久久久久久免费高清国产稀缺| 国产伦人伦偷精品视频| 午夜免费鲁丝| 亚洲精品久久成人aⅴ小说| 久久久精品国产亚洲av高清涩受| 亚洲精品成人av观看孕妇| 18禁美女被吸乳视频| 成人精品一区二区免费| 亚洲第一青青草原| 亚洲成国产人片在线观看| 色哟哟哟哟哟哟| 亚洲黑人精品在线| 欧美日韩国产mv在线观看视频| 岛国视频午夜一区免费看| 老司机午夜福利在线观看视频| 女人被躁到高潮嗷嗷叫费观| 一级,二级,三级黄色视频| 亚洲欧美日韩高清在线视频| 在线观看免费视频网站a站| 97超级碰碰碰精品色视频在线观看| 亚洲午夜精品一区,二区,三区| 美女高潮到喷水免费观看| 亚洲欧洲精品一区二区精品久久久| 身体一侧抽搐| 中亚洲国语对白在线视频| 久久精品亚洲精品国产色婷小说| 99在线人妻在线中文字幕| 久久久久精品国产欧美久久久| 久久国产乱子伦精品免费另类| 一区在线观看完整版| 黄色成人免费大全| 18禁美女被吸乳视频| 美女福利国产在线| 欧美黑人欧美精品刺激| √禁漫天堂资源中文www| av中文乱码字幕在线| 麻豆国产av国片精品| 一级黄色大片毛片| 狠狠狠狠99中文字幕| 亚洲午夜理论影院| 免费高清视频大片| 搡老乐熟女国产| av在线播放免费不卡| 最新在线观看一区二区三区| 成人av一区二区三区在线看| 日韩大码丰满熟妇| 日韩精品中文字幕看吧| 叶爱在线成人免费视频播放| 日日爽夜夜爽网站| 99热只有精品国产| 黑人猛操日本美女一级片| 欧美+亚洲+日韩+国产| 夜夜爽天天搞| 欧美 亚洲 国产 日韩一| 欧美激情极品国产一区二区三区| 国产aⅴ精品一区二区三区波| 国产又色又爽无遮挡免费看| 99久久精品国产亚洲精品| 99久久久亚洲精品蜜臀av| 在线观看午夜福利视频| 日韩精品中文字幕看吧| 欧美日韩亚洲综合一区二区三区_| 国产精品一区二区三区四区久久 | 一a级毛片在线观看| av片东京热男人的天堂| 午夜视频精品福利| 欧美成狂野欧美在线观看| 一级a爱视频在线免费观看| 免费女性裸体啪啪无遮挡网站| 国产成人精品久久二区二区免费| 亚洲熟妇中文字幕五十中出 | 在线免费观看的www视频| √禁漫天堂资源中文www| 欧美在线黄色| 桃色一区二区三区在线观看| 18禁观看日本| 亚洲一卡2卡3卡4卡5卡精品中文| 亚洲中文字幕日韩| 麻豆av在线久日| 欧美精品亚洲一区二区| 满18在线观看网站| 高清欧美精品videossex| 国产一区二区三区在线臀色熟女 | 黄色视频不卡| 精品久久久久久久久久免费视频 | 在线观看免费午夜福利视频| 身体一侧抽搐| 制服诱惑二区| 亚洲中文字幕日韩| 国产黄色免费在线视频| 九色亚洲精品在线播放| 精品福利永久在线观看| 激情在线观看视频在线高清| 久久精品国产亚洲av高清一级| 亚洲专区字幕在线| 久久中文字幕一级| 欧美乱码精品一区二区三区| 亚洲人成77777在线视频| 久久 成人 亚洲| 久久精品影院6| 我的亚洲天堂| 亚洲男人天堂网一区| 国产精品一区二区免费欧美| 黄片小视频在线播放| 中文字幕最新亚洲高清| 午夜免费观看网址| av天堂久久9| 一进一出好大好爽视频| 在线播放国产精品三级| 午夜福利一区二区在线看| 午夜成年电影在线免费观看| avwww免费| 国产成人啪精品午夜网站| 国产xxxxx性猛交| 老司机福利观看| 精品人妻1区二区| 操美女的视频在线观看| 99国产极品粉嫩在线观看| 老司机午夜十八禁免费视频| 亚洲伊人色综图| 性少妇av在线| 日本五十路高清| 夜夜夜夜夜久久久久| 亚洲自拍偷在线| 99久久综合精品五月天人人| 亚洲第一av免费看| 欧美日韩亚洲国产一区二区在线观看| 啦啦啦免费观看视频1| 人妻久久中文字幕网| 男人舔女人下体高潮全视频| 人妻久久中文字幕网| 男女下面进入的视频免费午夜 | 精品国产一区二区三区四区第35| 欧美一级毛片孕妇| 午夜福利欧美成人| 校园春色视频在线观看| 国产高清激情床上av| 精品久久久久久成人av| 一区二区日韩欧美中文字幕| 国产精品 欧美亚洲| 精品国产美女av久久久久小说| 搡老乐熟女国产| 美女高潮喷水抽搐中文字幕| 国产精品一区二区免费欧美| 亚洲成av片中文字幕在线观看| 日韩大尺度精品在线看网址 | 久久人妻熟女aⅴ| 色婷婷久久久亚洲欧美| av网站免费在线观看视频| 黄色成人免费大全| 嫁个100分男人电影在线观看| 久久精品91蜜桃| 超色免费av| 亚洲成人免费电影在线观看| 午夜精品在线福利| 欧美一区二区精品小视频在线| 国产成人一区二区三区免费视频网站| 精品人妻1区二区| 十分钟在线观看高清视频www| 色在线成人网| 成人三级做爰电影| 国产精品香港三级国产av潘金莲| 成人三级做爰电影| 黄色女人牲交| 国产精品一区二区免费欧美| 欧美日本中文国产一区发布| 久久热在线av| 美女高潮到喷水免费观看| 亚洲一区二区三区不卡视频| 成年人黄色毛片网站| 国产又爽黄色视频| 欧美最黄视频在线播放免费 | 美国免费a级毛片| 国产精品成人在线| 欧美在线黄色| 成人精品一区二区免费| 十八禁人妻一区二区| 久久国产乱子伦精品免费另类| 亚洲欧美日韩高清在线视频| 人成视频在线观看免费观看| 99久久人妻综合| xxx96com| 国产成人精品无人区| 女人被躁到高潮嗷嗷叫费观| 免费av中文字幕在线| 大陆偷拍与自拍| 少妇 在线观看| 国产亚洲欧美98| 十八禁网站免费在线| 成年版毛片免费区| aaaaa片日本免费| 亚洲成人国产一区在线观看| 不卡av一区二区三区| 在线观看日韩欧美| 免费av毛片视频| 又黄又粗又硬又大视频| 麻豆国产av国片精品| 巨乳人妻的诱惑在线观看| 真人做人爱边吃奶动态| 超色免费av| 欧美在线黄色| 丝袜美足系列| 午夜精品在线福利| 一区二区日韩欧美中文字幕| 国产熟女xx| 波多野结衣一区麻豆| 久久精品国产亚洲av香蕉五月| 好看av亚洲va欧美ⅴa在| 中文欧美无线码| av欧美777| 在线观看舔阴道视频| 国产av又大| 国产免费av片在线观看野外av| 国产成+人综合+亚洲专区| 这个男人来自地球电影免费观看| 免费在线观看影片大全网站| 欧美丝袜亚洲另类 | 丝袜在线中文字幕| 久久性视频一级片| 亚洲精品成人av观看孕妇| 精品国产一区二区久久| 一级a爱片免费观看的视频| 成人18禁高潮啪啪吃奶动态图| 90打野战视频偷拍视频| 黄色成人免费大全|